<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="301">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 24, 2013</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01622868</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-01977</org_study_id>
    <secondary_id>RTOG-1119</secondary_id>
    <secondary_id>U10CA021661</secondary_id>
    <secondary_id>CDR0000735353</secondary_id>
    <nct_id>NCT01622868</nct_id>
  </id_info>
  <brief_title>Whole-Brain Radiation Therapy With or Without Lapatinib Ditosylate in Treating Patients With Brain Metastasis From HER2-Positive Breast Cancer</brief_title>
  <official_title>Phase II Randomized Study of Whole Brain Radiotherapy in Combination With Concurrent Lapatinib in Patients With Brain Metastasis From HER2-Positive Breast Cancer: A Collaborative Study of RTOG and KROG</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized phase II trial studies how well whole-brain radiation therapy (WBRT) with or
      without lapatinib ditosylate works in treating patients with brain metastasis from
      HER2-positive breast cancer. Radiation therapy uses high energy x rays to kill tumor cells.
      Lapatinib ditosylate may stop the growth of tumor cells by blocking some of the enzymes
      needed for cell growth. It is not yet known whether radiation therapy together with
      lapatinib ditosylate is an effective treatment for brain metastasis from breast cancer
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To determine if there is a signal for an increase in complete response (CR) rate in the
      brain at 12 weeks post whole-brain radiotherapy (WBRT) as determined by magnetic-resonance
      imaging (MRI) scan of the brain, with the addition of lapatinib ditosylate (lapatinib) to
      WBRT compared to WBRT alone.

      SECONDARY OBJECTIVES:

      I. To evaluate CR rate in the brain at 4 weeks post WBRT as determined by MRI scan of the
      brain, with the addition of lapatinib to WBRT compared to WBRT alone.

      II. To evaluate objective response rate in the brain at 4 and 12 weeks post WBRT as
      determined by MRI scan of the brain, with the addition of lapatinib to WBRT compared to WBRT
      alone.

      III. To evaluate lesion-specific objective response rate (CR + partial response [PR]) at 4
      and 12 weeks post WBRT.

      IV. To evaluate overall response with addition of lapatinib to WBRT compared to WBRT alone.

      V. To evaluate the central nervous system (CNS) progression-free survival (PFS) rate and
      overall survival (OS) rate, with the addition of lapatinib to WBRT compared to WBRT alone.

      VI. To evaluate treatment-related adverse events when adding lapatinib to WBRT compared to
      WBRT alone.

      OUTLINE: This is a multicenter study. Patients are stratified according to graded prognostic
      assessment for breast cancer (II vs III vs IV), use of concurrent trastuzumab (yes vs no),
      use of non-CNS-penetrating HER2 blockade at time of study entry (none vs trastuzumab ±
      pertuzumab), and history of stereotactic radiosurgery (SRS) for limited brain metastasis (no
      vs yes). Patients are randomized to 1 of 2 treatment arms.

      Arm I: Patients undergo whole-brain radiation therapy (WBRT) once daily (QD) 5 days a week
      for 3 weeks in the absence of disease progression or unacceptable toxicity.

      Arm II: Patients receive lapatinib ditosylate orally (PO) QD on days 1-42 and undergo WBRT
      as in arm I in the absence of disease progression or unacceptable toxicity.

      After completion of study treatment, patients are followed up at 4 and 12 weeks and then
      every 12 weeks thereafter.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2012</start_date>
  <primary_completion_date type="Anticipated">July 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>CR rate in the brain measured by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 based on MRI scan of the brain</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>CR rate in the brain measured using revise RECIST version 1.1 based on MRI scan of the brain</measure>
    <time_frame>4 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR) (CR + PR) measured using RECIST version 1.1 based on MRI scan of the brain</measure>
    <time_frame>Up to 12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lesion-specific ORR (CR + PR)</measure>
    <time_frame>Up to 12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response (CR, PR, or stable disease [SD])</measure>
    <time_frame>Up to 2 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment-related toxicity as measured by Common Terminology Criterial for Adverse Events (CTCAE) version 4</measure>
    <time_frame>Up to 2 years</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CNS PFS</measure>
    <time_frame>From the time of randomization to the date of first failure (CNS progression or death due to any cause), assessed up to 2 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Estimated by the Kaplan-Meier method. Compared between arms using the log rank test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>From the date of randomization to the date of first failure or last follow-up, assessed up to 2 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Estimated by the Kaplan-Meier method. Compared between arms using the log rank test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>From the date of randomization to the date of first failure, assessed up to 2 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Estimated by the Kaplan-Meier method.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">143</enrollment>
  <condition>HER2-positive Breast Cancer</condition>
  <condition>Male Breast Cancer</condition>
  <condition>Recurrent Breast Cancer</condition>
  <condition>Stage IV Breast Cancer</condition>
  <condition>Tumors Metastatic to Brain</condition>
  <arm_group>
    <arm_group_label>Arm I (WBRT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo WBRT QD 5 days a week for 3 weeks in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (lapatinib ditosylate, WBRT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive lapatinib ditosylate PO QD on days 1-42 and undergo WBRT as in arm I in the absence of disease progression or unacceptable toxicity</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lapatinib ditosylate</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm II (lapatinib ditosylate, WBRT)</arm_group_label>
    <other_name>GSK572016</other_name>
    <other_name>GW-572016</other_name>
    <other_name>GW2016</other_name>
    <other_name>Lapatinib</other_name>
    <other_name>Tykerb</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>whole-brain radiation therapy</intervention_name>
    <description>Undergo WBRT</description>
    <arm_group_label>Arm I (WBRT)</arm_group_label>
    <arm_group_label>Arm II (lapatinib ditosylate, WBRT)</arm_group_label>
    <other_name>WBRT</other_name>
    <other_name>whole-brain radiotherapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pathologically (histologically or cytologically) proven diagnosis of invasive breast
             cancer

          -  Human epidermal growth factor receptor 2 (HER2)-overexpressing breast cancer (3+
             staining by immunohistochemistry or HER2 gene amplification by fluorescent in situ
             hybridization[FISH] or silver in situ hybridization [SISH] ≥ 2.2)

          -  Brain metastases that fulfill 1 of the following:

               -  Progressive parenchymal brain metastases following stereotactic radiosurgery for
                  1-3 brain metastases, with at least 1 new measurable lesion

               -  Progressive parenchymal brain metastases following surgical resection of 1-3
                  brain metastases, as long as at least 1 brain metastasis is measurable

          -  At least 1 measurable, unirradiated parenchymal brain lesion (≥ 10 mm on T1-weighted
             gadolinium-enhanced MRI) within 21 days prior to study entry

          -  No leptomeningeal disease

          -  Karnofsky performance status ≥ 60%

          -  Able to swallow and retain oral medication (Note: for patients unable to swallow
             tablets, an oral suspension preparation is acceptable)

          -  Absolute neutrophil count (ANC) ≥ 1,200 cells/mm³

          -  Platelets ≥ 70,000 cells/mm³

          -  Hemoglobin [Hgb] ≥ 8.0 g/dL (Note: The use of transfusion or other intervention to
             achieve Hgb ≥ 8.0 g/dL is acceptable)

          -  Creatinine &lt; 1.5 times institutional upper limit of normal (ULN)

          -  Bilirubin &lt; 1.5 times institutional ULN

          -  Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3.0 times
             institutional ULN with or without liver metastasis

          -  Women of childbearing potential must have a negative serum pregnancy test within 21
             days prior to study entry

          -  Sexually active women of childbearing potential and sexually active men must practice
             adequate contraception during therapy and for 12 months after protocol treatment
             completion

          -  Women should not breastfeed while on this study

          -  No uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
             arrhythmia, or psychiatric illness/social situations that would limit compliance with
             study requirements

          -  No prior invasive malignancy (except non-melanomatous skin cancer) unless disease
             free for a minimum of 3 years

          -  No severe, active co-morbidity, defined as follows:

               -  Unstable angina and/or congestive heart failure requiring hospitalization within
                  the last 6 months

               -  Transmural myocardial infarction within the last 6 months

               -  Acute bacterial or fungal infection requiring intravenous antibiotics at the
                  time of study entry

               -  Chronic obstructive pulmonary disease exacerbation or other respiratory illness
                  requiring hospitalization or precluding study therapy at the time of study entry

               -  Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects;
                  hepatic or biliary disease that is acute or currently active or that requires
                  antiviral therapy (with the exception of patients with Gilbert syndrome,
                  asymptomatic gallstones, liver metastases, or stable chronic liver disease per
                  investigator assessment)

               -  History of left ventricular ejection fraction (LVEF) below institutional normal
                  unless repeated and within institutional normal range within 90 days of study
                  entry

          -  No grade 2 or greater rash of any cause at time of study entry

          -  No grade 2 or greater diarrhea of any cause at time of study entry

          -  At least 14 days between FINAL dose of prior chemotherapy and study entry, with
             recovery of toxicities to grade 0 or 1

          -  No prior whole-brain radiation therapy (WBRT)

          -  No prior lapatinib therapy

          -  No prior radiotherapy to the region of the study cancer that would result in overlap
             of radiation therapy fields except patients who have progressed following
             stereotactic radiosurgery for 1-3 brain metastases, with at least one new lesion

          -  No concurrent intensity-modulated radiation therapy
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>In Ah Kim</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radiation Therapy Oncology Group</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer F. De Los Santos</last_name>
      <phone>205-934-0309</phone>
    </contact>
    <investigator>
      <last_name>Jennifer F. De Los Santos</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Kirklin Clinic at Acton Road</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35243</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer F. De Los Santos</last_name>
      <phone>205-934-0309</phone>
    </contact>
    <investigator>
      <last_name>Jennifer F. De Los Santos</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Christiana Care Health System-Christiana Hospital</name>
      <address>
        <city>Newark</city>
        <state>Delaware</state>
        <zip>19718</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adam Raben</last_name>
      <phone>302-733-6227</phone>
    </contact>
    <investigator>
      <last_name>Adam Raben</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northeast Georgia Medical Center</name>
      <address>
        <city>Gainesville</city>
        <state>Georgia</state>
        <zip>30501</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frank G. Lake</last_name>
      <phone>770-219-8800</phone>
      <email>cancerpatient.navigator@nghs.com</email>
    </contact>
    <investigator>
      <last_name>Frank G. Lake</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>John H Stroger Jr Hospital of Cook County</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612-3785</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>George R. Cybulsky</last_name>
      <phone>312-864-6000</phone>
    </contact>
    <investigator>
      <last_name>George R. Cybulsky</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Menorah Medical Center</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66209</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rakesh Gaur</last_name>
      <phone>913-948-5588</phone>
      <email>amy.krushelniski@hcahealthcare.com</email>
    </contact>
    <investigator>
      <last_name>Rakesh Gaur</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kansas City CCOP</name>
      <address>
        <city>Prairie Village</city>
        <state>Kansas</state>
        <zip>66208</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rakesh Gaur</last_name>
      <phone>913-948-5588</phone>
    </contact>
    <investigator>
      <last_name>Rakesh Gaur</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Boston Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Minh T. Truong</last_name>
      <phone>617-638-8265</phone>
    </contact>
    <investigator>
      <last_name>Minh T. Truong</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bronson Battle Creek</name>
      <address>
        <city>Battle Creek</city>
        <state>Michigan</state>
        <zip>49017</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gilbert D. Padula</last_name>
      <phone>616-685-5225</phone>
    </contact>
    <investigator>
      <last_name>Gilbert D. Padula</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Spectrum Health at Butterworth Campus</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gilbert D. Padula</last_name>
      <phone>616-685-5225</phone>
    </contact>
    <investigator>
      <last_name>Gilbert D. Padula</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Mary's Health Care</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gilbert D. Padula</last_name>
      <phone>616-685-5225</phone>
    </contact>
    <investigator>
      <last_name>Gilbert D. Padula</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Grand Rapids Clinical Oncology Program</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gilbert D. Padula</last_name>
      <phone>616-685-5225</phone>
    </contact>
    <investigator>
      <last_name>Gilbert D. Padula</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>West Michigan Cancer Center</name>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <zip>49007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raymond S. Lord</last_name>
      <phone>269-373-7458</phone>
    </contact>
    <investigator>
      <last_name>Raymond S. Lord</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bronson Methodist Hospital</name>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <zip>49007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raymond S. Lord</last_name>
      <phone>269-373-7458</phone>
    </contact>
    <investigator>
      <last_name>Raymond S. Lord</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Borgess Medical Center</name>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <zip>49001</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raymond S. Lord</last_name>
      <phone>269-373-7458</phone>
    </contact>
    <investigator>
      <last_name>Raymond S. Lord</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mercy Health Partners-Mercy Campus</name>
      <address>
        <city>Muskegon</city>
        <state>Michigan</state>
        <zip>49443</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gilbert D. Padula</last_name>
      <phone>616-685-5225</phone>
    </contact>
    <investigator>
      <last_name>Gilbert D. Padula</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fairview Ridges Hospital</name>
      <address>
        <city>Burnsville</city>
        <state>Minnesota</state>
        <zip>55337</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul W. Sperduto</last_name>
      <phone>952-993-1517</phone>
      <email>MMCCOP@parknicollet.com</email>
    </contact>
    <investigator>
      <last_name>Paul W. Sperduto</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mercy Hospital</name>
      <address>
        <city>Coon Rapids</city>
        <state>Minnesota</state>
        <zip>55433</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul W. Sperduto</last_name>
      <phone>952-993-1517</phone>
      <email>MMCCOP@parknicollet.com</email>
    </contact>
    <investigator>
      <last_name>Paul W. Sperduto</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fairview-Southdale Hospital</name>
      <address>
        <city>Edina</city>
        <state>Minnesota</state>
        <zip>55435</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul W. Sperduto</last_name>
      <phone>952-993-1517</phone>
      <email>MMCCOP@parknicollet.com</email>
    </contact>
    <investigator>
      <last_name>Paul W. Sperduto</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Unity Hospital</name>
      <address>
        <city>Fridley</city>
        <state>Minnesota</state>
        <zip>55432</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul W. Sperduto</last_name>
      <phone>952-993-1517</phone>
      <email>MMCCOP@parknicollet.com</email>
    </contact>
    <investigator>
      <last_name>Paul W. Sperduto</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Minnesota Oncology Hematology PA-Maplewood</name>
      <address>
        <city>Maplewood</city>
        <state>Minnesota</state>
        <zip>55109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul W. Sperduto</last_name>
      <phone>952-993-1517</phone>
      <email>MMCCOP@parknicollet.com</email>
    </contact>
    <investigator>
      <last_name>Paul W. Sperduto</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Abbott-Northwestern Hospital</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul W. Sperduto</last_name>
      <phone>952-993-1517</phone>
      <email>MMCCOP@parknicollet.com</email>
    </contact>
    <investigator>
      <last_name>Paul W. Sperduto</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hennepin County Medical Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55415</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul W. Sperduto</last_name>
      <phone>952-993-1517</phone>
      <email>MMCCOP@parknicollet.com</email>
    </contact>
    <investigator>
      <last_name>Paul W. Sperduto</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>North Memorial Medical Health Center</name>
      <address>
        <city>Robbinsdale</city>
        <state>Minnesota</state>
        <zip>55422</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul W. Sperduto</last_name>
      <phone>952-993-1517</phone>
      <email>MMCCOP@parknicollet.com</email>
    </contact>
    <investigator>
      <last_name>Paul W. Sperduto</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Metro-Minnesota CCOP</name>
      <address>
        <city>Saint Louis Park</city>
        <state>Minnesota</state>
        <zip>55416</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul W. Sperduto</last_name>
      <phone>952-993-1517</phone>
      <email>MMCCOP@parknicollet.com</email>
    </contact>
    <investigator>
      <last_name>Paul W. Sperduto</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Regions Hospital</name>
      <address>
        <city>Saint Paul</city>
        <state>Minnesota</state>
        <zip>55101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul W. Sperduto</last_name>
      <phone>952-993-1517</phone>
      <email>MMCCOP@parknicollet.com</email>
    </contact>
    <investigator>
      <last_name>Paul W. Sperduto</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>United Hospital</name>
      <address>
        <city>Saint Paul</city>
        <state>Minnesota</state>
        <zip>55102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul W. Sperduto</last_name>
      <phone>952-993-1517</phone>
      <email>MMCCOP@parknicollet.com</email>
    </contact>
    <investigator>
      <last_name>Paul W. Sperduto</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ridgeview Medical Center</name>
      <address>
        <city>Waconia</city>
        <state>Minnesota</state>
        <zip>55387</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul W. Sperduto</last_name>
      <phone>952-993-1517</phone>
      <email>MMCCOP@parknicollet.com</email>
    </contact>
    <investigator>
      <last_name>Paul W. Sperduto</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rice Memorial Hospital</name>
      <address>
        <city>Willmar</city>
        <state>Minnesota</state>
        <zip>56201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul W. Sperduto</last_name>
      <phone>952-993-1517</phone>
      <email>MMCCOP@parknicollet.com</email>
    </contact>
    <investigator>
      <last_name>Paul W. Sperduto</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Singing River Hospital</name>
      <address>
        <city>Pascagoula</city>
        <state>Mississippi</state>
        <zip>39581</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James E. Clarkson</last_name>
      <phone>228-809-5292</phone>
    </contact>
    <investigator>
      <last_name>James E. Clarkson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Research Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64132</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rakesh Gaur</last_name>
      <phone>913-948-5588</phone>
      <email>amy.krushelniski@hcahealthcare.com</email>
    </contact>
    <investigator>
      <last_name>Rakesh Gaur</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Luke's Hospital of Kansas City</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rakesh Gaur</last_name>
      <phone>913-948-5588</phone>
      <email>amy.krushelniski@hcahealthcare.com</email>
    </contact>
    <investigator>
      <last_name>Rakesh Gaur</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Heartland Regional Medical Center</name>
      <address>
        <city>Saint Joseph</city>
        <state>Missouri</state>
        <zip>64506</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rakesh Gaur</last_name>
      <phone>913-948-5588</phone>
      <email>amy.krushelniski@hcahealthcare.com</email>
    </contact>
    <investigator>
      <last_name>Rakesh Gaur</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Barnes West County Hospital</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Imran Zoberi</last_name>
      <phone>800-600-3606</phone>
      <email>info@ccadmin.wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Imran Zoberi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint John's Mercy Medical Center</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bethany G. Sleckman</last_name>
      <phone>913-948-5588</phone>
    </contact>
    <investigator>
      <last_name>Bethany G. Sleckman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Louis-Cape Girardeau CCOP</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bethany G. Sleckman</last_name>
      <phone>913-948-5588</phone>
    </contact>
    <investigator>
      <last_name>Bethany G. Sleckman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Imran Zoberi</last_name>
      <phone>800-600-3606</phone>
      <email>info@ccadmin.wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Imran Zoberi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Siteman Cancer Center - Saint Peters</name>
      <address>
        <city>Saint Peters</city>
        <state>Missouri</state>
        <zip>63376</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Imran Zoberi</last_name>
      <phone>800-600-3606</phone>
      <email>info@ccadmin.wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Imran Zoberi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint John's Hospital</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65804</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert L. Carolla</last_name>
      <phone>417-269-4520</phone>
    </contact>
    <investigator>
      <last_name>Robert L. Carolla</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cox Medical Center</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65807</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert L. Carolla</last_name>
      <phone>417-269-4520</phone>
    </contact>
    <investigator>
      <last_name>Robert L. Carolla</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ozark Health Ventures LLC dba Cancer Research for The Ozarks Springfield</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65802</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert L. Carolla</last_name>
      <phone>417-269-4520</phone>
    </contact>
    <investigator>
      <last_name>Robert L. Carolla</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Elliot Hospital</name>
      <address>
        <city>Manchester</city>
        <state>New Hampshire</state>
        <zip>03103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brian R. Knab</last_name>
      <phone>603-663-1800</phone>
    </contact>
    <investigator>
      <last_name>Brian R. Knab</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Barnabas Medical Center</name>
      <address>
        <city>Livingston</city>
        <state>New Jersey</state>
        <zip>07039</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rosemonde Z. Woel</last_name>
      <phone>973-322-2470</phone>
    </contact>
    <investigator>
      <last_name>Rosemonde Z. Woel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hematology Oncology Associates of Central New York PC</name>
      <address>
        <city>East Syracuse</city>
        <state>New York</state>
        <zip>13057</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dennis J. Kotlove</last_name>
      <phone>315-472-7504</phone>
    </contact>
    <investigator>
      <last_name>Dennis J. Kotlove</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Rochester</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuhchyau Chen</last_name>
      <phone>585-275-5830</phone>
    </contact>
    <investigator>
      <last_name>Yuhchyau Chen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Highland Hospital</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14620</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuhchyau Chen</last_name>
      <phone>585-275-5830</phone>
    </contact>
    <investigator>
      <last_name>Yuhchyau Chen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Akron General Medical Center</name>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <zip>44307</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mitchel L. Fromm</last_name>
      <phone>330-344-6348</phone>
    </contact>
    <investigator>
      <last_name>Mitchel L. Fromm</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Summa Akron City Hospital</name>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <zip>44304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charles A. Kunos</last_name>
      <phone>800-641-2422</phone>
    </contact>
    <investigator>
      <last_name>Charles A. Kunos</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Radiation Oncology Center</name>
      <address>
        <city>Alliance</city>
        <state>Ohio</state>
        <zip>44601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>William F. Demas</last_name>
      <phone>330-615-4132</phone>
    </contact>
    <investigator>
      <last_name>William F. Demas</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Summa Barberton Hospital</name>
      <address>
        <city>Barberton</city>
        <state>Ohio</state>
        <zip>44203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charles A. Kunos</last_name>
      <phone>800-641-2422</phone>
    </contact>
    <investigator>
      <last_name>Charles A. Kunos</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mercy Medical Center</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44708</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Edward J. Walsh</last_name>
      <phone>888-293-4673</phone>
    </contact>
    <investigator>
      <last_name>Edward J. Walsh</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ohio State University Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Allison M. Quick</last_name>
      <phone>866-627-7616</phone>
      <email>osu@emergingmed.com</email>
    </contact>
    <investigator>
      <last_name>Allison M. Quick</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cancer Care Center, Incorporated</name>
      <address>
        <city>Salem</city>
        <state>Ohio</state>
        <zip>44460</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>William F. Demas</last_name>
      <phone>330-615-4132</phone>
    </contact>
    <investigator>
      <last_name>William F. Demas</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cancer Treatment Center</name>
      <address>
        <city>Wooster</city>
        <state>Ohio</state>
        <zip>44691</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>William F. Demas</last_name>
      <phone>330-615-4132</phone>
    </contact>
    <investigator>
      <last_name>William F. Demas</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Natalie W Bryant Cancer Center</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charles E. Stewart</last_name>
      <phone>918-494-2200</phone>
    </contact>
    <investigator>
      <last_name>Charles E. Stewart</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Abington Memorial Hospital</name>
      <address>
        <city>Abington</city>
        <state>Pennsylvania</state>
        <zip>19001</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wayne H. Pinover</last_name>
      <phone>215-481-2402</phone>
    </contact>
    <investigator>
      <last_name>Wayne H. Pinover</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicole L. Simone</last_name>
      <phone>215-955-6084</phone>
    </contact>
    <investigator>
      <last_name>Nicole L. Simone</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Reading Hospital and Medical Center</name>
      <address>
        <city>West Reading</city>
        <state>Pennsylvania</state>
        <zip>19612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Albert Yuen</last_name>
      <phone>610-988-9323</phone>
    </contact>
    <investigator>
      <last_name>Albert Yuen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Vincent Hospital</name>
      <address>
        <city>Green Bay</city>
        <state>Wisconsin</state>
        <zip>54301</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gregory M. Cooley</last_name>
      <phone>920-433-8889</phone>
    </contact>
    <investigator>
      <last_name>Gregory M. Cooley</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Green Bay Oncology at Saint Vincent Hospital</name>
      <address>
        <city>Green Bay</city>
        <state>Wisconsin</state>
        <zip>54301-3526</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Saint Mary's Hospital</name>
      <address>
        <city>Green Bay</city>
        <state>Wisconsin</state>
        <zip>54303</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gregory M. Cooley</last_name>
      <phone>920-433-8889</phone>
    </contact>
    <investigator>
      <last_name>Gregory M. Cooley</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin Hospital and Clinics</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bethany M. Anderson</last_name>
      <phone>877-405-6866</phone>
    </contact>
    <investigator>
      <last_name>Bethany M. Anderson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Holy Family Memorial Hospital</name>
      <address>
        <city>Manitowoc</city>
        <state>Wisconsin</state>
        <zip>54221</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gregory M. Cooley</last_name>
      <phone>920-433-8889</phone>
    </contact>
    <investigator>
      <last_name>Gregory M. Cooley</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bay Area Medical Center</name>
      <address>
        <city>Marinette</city>
        <state>Wisconsin</state>
        <zip>54143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gregory M. Cooley</last_name>
      <phone>920-433-8889</phone>
    </contact>
    <investigator>
      <last_name>Gregory M. Cooley</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Door County Cancer Center</name>
      <address>
        <city>Sturgeon Bay</city>
        <state>Wisconsin</state>
        <zip>54235-1495</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gregory M. Cooley</last_name>
      <phone>920-433-8889</phone>
    </contact>
    <investigator>
      <last_name>Gregory M. Cooley</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Cancer Center-Korea</name>
      <address>
        <city>Goyang-si</city>
        <state>Gyeonggi-do</state>
        <zip>410-769</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kwan H. Cho</last_name>
      <phone>215-574-3173</phone>
    </contact>
    <investigator>
      <last_name>Kwan H. Cho</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <state>Korea</state>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Doo Ho Choi</last_name>
      <phone>011-82-1599-3114</phone>
    </contact>
    <investigator>
      <last_name>Doo Ho Choi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gangnam Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ki Chang Keum</last_name>
      <phone>215-574-3173</phone>
    </contact>
    <investigator>
      <last_name>Ki Chang Keum</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <lastchanged_date>May 31, 2013</lastchanged_date>
  <firstreceived_date>June 15, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Breast Neoplasms, Male</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lapatinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
